文献速递心血管CTMRUSPET

肥厚型心肌病的多模态影像学综述:诊断、风险分层与治疗指导

A Review of Multimodality Imaging in Hypertrophic Cardiomyopathy: Diagnosis, Risk Stratification, and Therapeutic Guidance.
PubMed 文献 · Radiol Cardiothorac Imaging · 2025-01-01

本综述阐述超声心动图、心血管MRI、核医学成像与心脏CT在肥厚型心肌病中的应用。超声心动图是主要工具,评估左心室壁厚度、流出道压差与二尖瓣形态;心血管MRI补充组织特征与预后评估;核医学成像用于识别转甲状腺素蛋白淀粉样变与结节病等表型模拟;心脏CT用于室间隔减容治疗前评估冠状动脉解剖。整合多模态方法可实现精准诊断、稳健风险分层与个体化治疗规划。

要点

  • 超声心动图是肥厚型心肌病的主要影像工具,评估室壁厚度、流出道压差与二尖瓣形态。
  • 心血管MRI通过晚期钆增强与细胞外容积测量增强预后评估与风险分层。
  • 核医学成像对识别转甲状腺素蛋白淀粉样变与结节病等表型模拟具有关键作用。

核心结论

  • 多模态影像整合方法可对肥厚型心肌病实现精准诊断、稳健风险分层与个体化治疗规划。
  • 每种模态贡献独特优势,共同增强临床决策并优化患者结局。

研究设计与样本

  • 本文为综述,纳入超声心动图、心血管MRI、核医学成像与心脏CT在肥厚型心肌病诊断、风险分层与治疗指导中的多模态影像学应用。

关键影像表现/征象

  • 超声心动图评估左心室壁厚度、流出道压差与二尖瓣形态。
  • 负荷超声心动图对检测梗阻性肥厚型心肌病的动态压差及支持心肌切除术等干预的术前规划特别有价值。
  • 心血管MRI具有更高分辨率,可详细评估心肌质量、血流动力学与全面组织特征。
  • 晚期钆增强与细胞外容积测量增强预后评估与风险分层。
  • 心脏MRI有助于区分肥厚型心肌病与浸润性或贮积性疾病等表型模拟,并检测心肌排列紊乱、微血管功能障碍与心肌代谢异常。

临床应用与阅片要点

  • 超声心动图作为主要影像工具,提供诊断信息并指导治疗决策。
  • 负荷超声心动图用于检测梗阻性肥厚型心肌病的动态压差并支持心肌切除术等干预的术前规划。
  • 心血管MRI通过晚期钆增强与细胞外容积测量用于预后评估与风险分层。
  • 心脏MRI用于帮助区分肥厚型心肌病与浸润性或贮积性疾病等表型模拟。
  • 心脏CT用于考虑室间隔减容治疗患者的冠状动脉解剖评估,确保全面术前评估。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Hypertrophic cardiomyopathy (HCM) requires multimodality imaging for accurate diagnosis, risk assessment, and management strategies. Echocardiography serves as the primary imaging tool, evaluating left ventricular wall thickness, outflow tract gradients, and mitral valve morphology. It provides essential diagnostic information and guides treatment decisions, with stress echocardiography particularly valuable for detecting dynamic gradients in obstructive HCM and supporting preoperative planning for interventions such as myectomy. Cardiovascular MRI complements echocardiography through superior resolution, enabling detailed assessment of myocardial mass, flow dynamics, and comprehensive tissue characterization. Late gadolinium enhancement and extracellular volume measurements enhance prognostic evaluation and risk stratification. Cardiac MRI excels at helping distinguish HCM from phenocopies like infiltrative or storage diseases and detecting myocardial disarray, microvascular dysfunction, and abnormalities in myocardial metabolism. Nuclear imaging proves crucial for identifying HCM phenocopies, including transthyretin amyloidosis and sarcoidosis, providing specific diagnostic capabilities. Cardiac CT, while having a secondary diagnostic role, becomes invaluable for evaluating coronary anatomy in patients considered for septal reduction therapies, ensuring comprehensive preoperative assessment. This integrated multimodal approach provides comprehensive HCM evaluation, enabling precise diagnosis, robust risk stratification, and individualized treatment planning. Each modality contributes unique strengths that collectively enhance clinical decision-making and optimize patient outcomes in this complex myocardial disease. Keywords: Cardiomyopathies, Applications-Multimodal, CT, Echocardiography, MR Imaging, SPECT, SPECT/CT, Cardiac Supplemental material is available for this article. © RSNA, 2025.

来源:Radiol Cardiothorac Imaging,查看原文。版权归原作者所有。

引用

  1. Gandhi R, Ooi EL, Mugwagwa A, et al. A Review of Multimodality Imaging in Hypertrophic Cardiomyopathy: Diagnosis, Risk Stratification, and Therapeutic Guidance. Radiol Cardiothorac Imaging. 2025. PMID: 41231126. doi:10.1148/ryct.240555

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。